Business Context and Reporting Period
Autolus Therapeutics Plc filed a Form 8-K on July 30, 2026, reporting the entry into a material definitive agreement. The company, incorporated in England and Wales, operates in the biotechnology sector and trades on the Nasdaq Global Select Market under the symbol AUTL.
Key Financial Metrics and Transaction Details
The filing details a new senior secured notes facility with Perceptive Credit Holdings V, LP. Key financial terms include:
- Total Facility Size: Up to $250.0 million in aggregate principal amount.
- Initial Drawdown (Tranche 1): $75.0 million issued on the closing date.
- Future Tranches:
- Tranche 2: Up to $25.0 million available through January 30, 2027.
- Tranche 3: Up to $75.0 million contingent on achieving specific Consolidated Net Revenue levels by July 31, 2028.
- Tranche 4: Up to $75.0 million contingent on achieving specific Consolidated Net Revenue levels by January 31, 2030.
- Interest Rate: Applicable margin of 6.75% to 7.25% (based on revenue) plus the greater of one-month term SOFR or 3.50%.
- Maturity Date: July 30, 2031.
- Warrants Issued: 3,500,000 warrants to purchase ADSs at an exercise price of $1.9314 per ADS (25% premium to 30-day VWAP). Additional warrants of 2,500,000 ADSs each may be issued upon Tranche 3 and Tranche 4 closings.
- Collateral: First priority security interest on substantially all existing and after-acquired assets of the Company and subsidiary guarantors.
Material Changes and Covenants
This transaction represents a significant change in the company's capital structure, introducing a new debt obligation and equity-linked warrants. The Note Purchase Agreement includes specific financial covenants:
- Minimum Liquidity: The company must maintain a Minimum Liquidity Amount ranging from $12.5 million to $50.0 million, depending on revenue and market capitalization thresholds.
- Revenue Covenants: The company must maintain Consolidated Net Revenue not less than amounts specified in the agreement to access future tranches.
- Default Consequences: An event of default triggers an interest rate increase of 4.00% per annum and potential acceleration of all outstanding principal and interest.
Guidance, Risks, and Unusual Items
The filing does not provide updated financial guidance or management commentary regarding future revenue projections beyond the revenue thresholds required for tranche availability. Key risks and contingencies identified include:
- Revenue Dependency: Access to $150.0 million of the facility (Tranches 3 and 4) is contingent on meeting specific revenue milestones.
- Dilution Risk: The issuance of warrants (up to 8,500,000 ADSs total) creates potential dilution for existing shareholders.
- Liquidity Constraints: The company is subject to strict minimum liquidity covenants; failure to maintain these could result in a default.
- Early Redemption: The company may redeem notes prior to maturity subject to a premium ranging from 1% to 8%.
Investor Verification Checklist
- Verify the specific Consolidated Net Revenue thresholds required to unlock Tranches 3 and 4 in the full Note Purchase Agreement.
- Confirm the current cash and cash equivalents balance to assess compliance with the $12.5 million to $50.0 million Minimum Liquidity covenant.
- Review the full warrant agreement for anti-dilution adjustments and specific terms regarding cashless exercise.
- Assess the impact of the new debt service obligations (interest payments) on the company's projected cash burn rate.
- Check for any existing debt that may be subordinated to or affected by this new senior secured facility.